Literature DB >> 21163447

Acute encephalopathy with inflammation-mediated status epilepticus.

Rima Nabbout1, Annamaria Vezzani, Olivier Dulac, Catherine Chiron.   

Abstract

Fever-induced refractory epileptic encephalopathy in school-aged children (FIRES), and idiopathic hemiconvulsion-hemiplegia syndrome (IHHS) are both triggered by fever, although evidence for a causal microorganism or an autoimmune phenomenon is lacking. FIRES begins in school age with status epilepticus lasting several weeks, involves perisylvian areas including mesial temporal structures, and is followed by pharmacoresistant epilepsy with major cognitive deterioration. IHHS begins in infancy with unilateral clonic status epilepticus and is followed by hemiplegia with pharmacoresistant epilepsy. The aetiology of FIRES and IHHS remains unknown, although clinical features and experimental models point to a likely vicious cycle involving inflammation and seizure activity that depends on the stage of brain maturation. We therefore propose to group these conditions under the concept of acute encephalopathy with inflammation-mediated status epilepticus. In addition to preliminary but encouraging clinical observations, there are theoretical reasons to consider the ketogenic diet as an early means to control both seizures and inflammation.

Entities:  

Mesh:

Year:  2011        PMID: 21163447     DOI: 10.1016/S1474-4422(10)70214-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  37 in total

1.  The blood-brain barrier hypothesis in drug resistant epilepsy.

Authors:  Nicola Marchi; Tiziana Granata; Andreas Alexopoulos; Damir Janigro
Journal:  Brain       Date:  2012-01-16       Impact factor: 13.501

Review 2.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

Review 3.  Inflammatory pathways of seizure disorders.

Authors:  Nicola Marchi; Tiziana Granata; Damir Janigro
Journal:  Trends Neurosci       Date:  2013-12-16       Impact factor: 13.837

4.  Intracellular and circulating neuronal antinuclear antibodies in human epilepsy.

Authors:  Philip H Iffland; Juliana Carvalho-Tavares; Abhishek Trigunaite; Shumei Man; Peter Rasmussen; Andreas Alexopoulos; Chaitali Ghosh; Trine N Jørgensen; Damir Janigro
Journal:  Neurobiol Dis       Date:  2013-07-21       Impact factor: 5.996

Review 5.  The role of adenosine in epilepsy.

Authors:  Landen Weltha; Jesica Reemmer; Detlev Boison
Journal:  Brain Res Bull       Date:  2018-11-20       Impact factor: 4.077

6.  Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.

Authors:  Detlev Boison; Susan A Masino; Jonathan D Geiger
Journal:  Expert Opin Drug Discov       Date:  2011-07       Impact factor: 6.098

Review 7.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 8.  Autoimmune seizures and epilepsy.

Authors:  Christian Geis; Jesus Planagumà; Mar Carreño; Francesc Graus; Josep Dalmau
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

Review 9.  Breakdown of blood brain barrier as a mechanism of post-traumatic epilepsy.

Authors:  Aaron Dadas; Damir Janigro
Journal:  Neurobiol Dis       Date:  2018-07-18       Impact factor: 5.996

10.  ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus.

Authors:  Mayu Shinohara; Makiko Saitoh; Daisuke Nishizawa; Kazutaka Ikeda; Shinichi Hirose; Jun-ichi Takanashi; Junko Takita; Kenjiro Kikuchi; Masaya Kubota; Gaku Yamanaka; Takashi Shiihara; Akira Kumakura; Masahiro Kikuchi; Mitsuo Toyoshima; Tomohide Goto; Hideo Yamanouchi; Masashi Mizuguchi
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.